Overview

Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
Multi-centre, randomised, parallel-group study, rater-blinded. Total duration of the study per subject is 12 weeks plus a one- to two-week screening period. There are 6 pre-planned visits per subject: screening visit followed by 5 visits. Approximately 300 patients altogether in up to 25 active German study centres and up to 3 active Lithuanian study centres will be randomised.
Phase:
Phase 4
Details
Lead Sponsor:
Orion Corporation, Orion Pharma
Treatments:
Cabergoline
Entacapone
Levodopa